Literature DB >> 16634641

Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants.

Forrester J Liddle1, James V Alvarez, Valeria Poli, David A Frank.   

Abstract

Aberrant activation of STAT transcription factors has been implicated in a variety of cancers. Constitutively active forms of STAT1 and STAT3 (STAT1C and STAT3C) have been developed to determine the effects of STAT activation in isolation from other cytokine-stimulated signaling pathways. These mutants were created by engineering cysteine residues into the carboxy terminus of each STAT molecule, allowing a hypothesized disulfide bond to form between two unphosphorylated monomers. To determine whether the presence of cysteine residues is sufficient to allow for functional activation in the absence of tyrosine phosphorylation, we developed STAT1C and STAT3C mutants that are unable to be phosphorylated on the critical tyrosine residue. Without the tyrosine residue, cysteine containing constitutive STAT mutants failed to transactivate STAT target genes. Furthermore, transfection of STAT dominant negative mutants prevented the activation of STAT1C and STAT3C. Cytokine-induced activation of STAT1C and STAT3C was dramatically prolonged when compared to wild-type proteins and led to extended STAT-dependent gene activation. These data show that tyrosine phosphorylation is required for activation of STAT1C and STAT3C. Additionally, these findings suggest the existence of basal phosphorylation that is a dynamic process that involves both phosphorylation and dephosphorylation. The constitutive STAT mutants likely show heightened activity because of the cysteine residues stabilizing these dimers and preventing dephosphorylation, resulting in the accumulation of trancriptionally active STAT dimer complexes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16634641     DOI: 10.1021/bi0525674

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Characterization of a dominant-active STAT that promotes tumorigenesis in Drosophila.

Authors:  Laura A Ekas; Timothy J Cardozo; Maria Sol Flaherty; Elizabeth A McMillan; Foster C Gonsalves; Erika A Bach
Journal:  Dev Biol       Date:  2010-05-23       Impact factor: 3.582

2.  Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development.

Authors:  Ralf Buettner; Renzo Corzano; Rumana Rashid; Jianping Lin; Maheswari Senthil; Michael Hedvat; Anne Schroeder; Allen Mao; Andreas Herrmann; John Yim; Hongzhi Li; Yate-Ching Yuan; Kenichi Yakushijin; Fumiko Yakushijin; Nagarajan Vaidehi; Roger Moore; Gabriel Gugiu; Terry D Lee; Richard Yip; Yuan Chen; Richard Jove; David Horne; John C Williams
Journal:  ACS Chem Biol       Date:  2011-02-16       Impact factor: 5.100

3.  STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents.

Authors:  Sarah R Walker; Mousumi Chaudhury; David A Frank
Journal:  Mol Cell Pharmacol       Date:  2011-01-01

Review 4.  Concise Review: Reprogramming, Behind the Scenes: Noncanonical Neural Stem Cell Signaling Pathways Reveal New, Unseen Regulators of Tissue Plasticity With Therapeutic Implications.

Authors:  Steven W Poser; Josh G Chenoweth; Carlo Colantuoni; Jimmy Masjkur; George Chrousos; Stefan R Bornstein; Ronald D McKay; Andreas Androutsellis-Theotokis
Journal:  Stem Cells Transl Med       Date:  2015-09-14       Impact factor: 6.940

5.  Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.

Authors:  Eirini Pectasides; Ann-Marie Egloff; Clarence Sasaki; Panteleimon Kountourakis; Barbara Burtness; George Fountzilas; Urania Dafni; Thomas Zaramboukas; Theodoros Rampias; David Rimm; Jennifer Grandis; Amanda Psyrri
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

6.  Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation.

Authors:  Belen Elguero; Geraldine Gueron; Jimena Giudice; Martin A Toscani; Paola De Luca; Florencia Zalazar; Federico Coluccio-Leskow; Roberto Meiss; Nora Navone; Adriana De Siervi; Elba Vazquez
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

7.  STAT3 protein up-regulates Gα-interacting vesicle-associated protein (GIV)/Girdin expression, and GIV enhances STAT3 activation in a positive feedback loop during wound healing and tumor invasion/metastasis.

Authors:  Ying Dunkel; Andrew Ong; Dimple Notani; Yash Mittal; Michael Lam; Xiaoyi Mi; Pradipta Ghosh
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

8.  SH2 modified STAT1 induces HLA-I expression and improves IFN-γ signaling in IFN-α resistant HCV replicon cells.

Authors:  Bret Poat; Sidhartha Hazari; Partha K Chandra; Feyza Gunduz; Luis A Balart; Xavier Alvarez; Srikanta Dash
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

9.  A point mutation, E95D, in the mumps virus V protein disengages STAT3 targeting from STAT1 targeting.

Authors:  Mamta Puri; Ken Lemon; W Paul Duprex; Bertus K Rima; Curt M Horvath
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

10.  MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion.

Authors:  Jingchun Gao; Matthew J McConnell; Bin Yu; Jiannong Li; Justin M Balko; Esther P Black; Joseph O Johnson; Mark C Lloyd; Soner Altiok; Eric B Haura
Journal:  Int J Oncol       Date:  2009-08       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.